Why isn't an oncogenic mutation in KRAS enough to induce and sustain transformation?
1/5 보강
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.7%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
KRAS, a key member of the RAS proto-oncogene family, encodes a small GTPase involved in regulating cell proliferation, differentiation, and survival through signaling cascades such as MAPK/ERK, PI3K/A
APA
Iovanna J, Dusetti N (2026). Why isn't an oncogenic mutation in KRAS enough to induce and sustain transformation?. Critical reviews in oncology/hematology, 219, 105110. https://doi.org/10.1016/j.critrevonc.2025.105110
MLA
Iovanna J, et al.. "Why isn't an oncogenic mutation in KRAS enough to induce and sustain transformation?." Critical reviews in oncology/hematology, vol. 219, 2026, pp. 105110.
PMID
41506499 ↗
Abstract 한글 요약
KRAS, a key member of the RAS proto-oncogene family, encodes a small GTPase involved in regulating cell proliferation, differentiation, and survival through signaling cascades such as MAPK/ERK, PI3K/AKT/mTOR, RalGEF/RalA/B, JAK/STAT3, and NF-κB. Although KRAS mutations, especially at codons 12, 13, or 61, lead to its activation and contribute to uncontrolled growth, these changes alone are not enough to fully transform a normal cell. KRAS activation requires cooperation with other genetic or epigenetic events, such as inactivation of p53 or p16, tumor suppressor genes to overcome critical cellular barriers, for example, senescence and apoptosis. This need for cooperation reflects the complexity of the oncogenic process, requiring simultaneous deregulation of multiple signaling pathways for malignant transformation. Indeed, in experimental models, mutant KRAS expression in normal cells often induces oncogene-induced senescence rather than unlimited proliferation. These findings highlight that KRAS functions more as an initiator of tumorigenesis than as an autonomous driver. Thus, in depth understanding of the genetic context in which KRAS operates is essential for the development of effective and personalized therapeutic strategies.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.